Streetbeat News

Stock Prices

BOX

MSFT

Box Inc (NYSE:BOX) reported Q4 earnings with a slight revenue miss and an EPS beat, alongside an expanded AI partnership with Microsoft (NASDAQ:MSFT), driving its shares up in after-hours trading. Q4 revenue was $262.88 million, slightly below estimates, while EPS was 42 cents, above expectations. The company saw a 2% year-over-year revenue increase and a 6% increase in billings. Box anticipates Q1 revenue to be slightly above estimates and provided a fiscal-year 2025 revenue forecast slightly below expectations. The partnership with Microsoft aims to integrate Box AI with Microsoft Azure OpenAI Service, enhancing Box's AI capabilities for Enterprise Plus plan customers.

Portfolio Pulse from Adam Eckert

March 05, 2024 | 9:45 pm

MLNK

MeridianLink has projected its FY24 revenue to be between $313.0M and $323.0M, which is below the estimated $329.197M.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:45 pm

MEC

Mayville Engineering (NYSE:MEC) reported Q4 earnings with an EPS of $0.21, beating estimates by 62.0% against an expected $0.13. Revenue increased by $20.05 million from the same period last year. In the previous quarter, MEC missed EPS estimates by $0.01, leading to a 3.0% share price drop the following day.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 9:45 pm

EVC

Entravision Comms (NYSE:EVC) reported Q4 earnings with an EPS of $-0.21, missing estimates by -400.0% against an expected $0.07. Revenue increased by $23.73 million from the same period last year. Despite missing EPS estimates last quarter, the share price increased by 8.0% the following day. Historical performance shows mixed results in meeting EPS estimates over the past year.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 9:45 pm

MEC

Mayville Engineering (NYSE:MEC) reported Q4 2023 adjusted EPS of $0.21, surpassing the $0.13 estimate, but missed sales estimates with $148.58M against the expected $152.31M. This represents a 15.60% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:43 pm

FTEL

Fitell Corporation (NASDAQ:FTEL), an Australian online retailer of gym and fitness equipment, reported a significant decrease in H1 revenue and gross profit for the period ending December 31, 2023. Revenue fell by 30.5% to $2.1M, and gross profit dropped by 46.8% to $0.85M compared to the same period in 2022. The decline was attributed to decreased merchandise revenue, absence of sales in consumable products, and reduced licensing income. Despite a 34.3% increase in sales orders, the average revenue per order fell by 30.5%, mainly due to consumer spending changes. The company also faced increased expenses, including consulting fees and general and administrative costs, leading to a net loss of $2.66M, significantly higher than the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:41 pm

PKOH

Park-Ohio Holdings (NASDAQ:PKOH) reported Q4 earnings with an EPS of $0.54, missing estimates by -2.0% against an expected $0.55. Revenue increased by $7.70 million from the previous year. In contrast, the company had previously beaten EPS estimates in Q3 2023, leading to a 21.0% share price increase the following day.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 9:40 pm

PKOH

Park-Ohio Holdings (PKOH) reported Q4 2023 adjusted EPS of $0.540, missing the $0.560 estimate, but sales of $389.3M exceeded the $386.45M estimate. This represents a 700% increase in EPS from the previous year and a 2.02% increase in sales.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:37 pm

NPCE

NeuroPace (NASDAQ:NPCE) reported Q4 earnings with an EPS of $-0.23, beating estimates by 26.0% and showing a revenue increase of $5.22 million from the previous year. Despite past earnings beats, such as last quarter's $0.13 EPS beat, the share price dropped 2.0% the following day. The company has consistently outperformed EPS estimates over the past four quarters.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 9:35 pm

RAPT

RAPT Therapeutics, Inc. (NASDAQ:RAPT) announced the acceptance of three late-breaking abstracts for presentation at the AACR Annual Meeting in April 2024, including phase 2 clinical data on tivumecirnon (FLX475) for head and neck squamous cell carcinoma. The presentations will cover the efficacy of FLX475 in combination with pembrolizumab, a combined mregDC and Treg signature's association with antitumor efficacy, and the role of HPK1 in CD8+ T cell effector gene expression.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:34 pm